Joseph P. Lyssikatos, Ph.D.

Joseph P. Lyssikatos, Ph.D.

Chief Scientific OfficeratEnliven Therapeutics· In proxies 2022–2024

Pay in FY2023+649% from the year before · Enliven Therapeutics stock -15.4% the same year

Joseph P. Lyssikatos, Ph.D. was paid $4.0M in FY2023 (Dec), up 649%. Enliven Therapeutics stock fell 15.4% that year.

Pay$100 in the stock at the end of FY21 → $154
Pay is from the Summary Compensation Table of each Enliven Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Enliven TherapeuticsPublic company · 4 yr
    • Chief Scientific Officer2022 – Present · 4 yrStock in role +357%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?